These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 10322503)

  • 1. Poly (ADP-ribose) polymerase, nitric oxide and cell death.
    Pieper AA; Verma A; Zhang J; Snyder SH
    Trends Pharmacol Sci; 1999 Apr; 20(4):171-81. PubMed ID: 10322503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase].
    Boulu RG; Mesenge C; Charriaut-Marlangue C; Verrecchia C; Plotkine M
    Bull Acad Natl Med; 2001; 185(3):555-63; discussion 564-5. PubMed ID: 11501263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of NADPH oxidase and neuronal nitric oxide synthase in zinc-induced poly(ADP-ribose) polymerase activation and cell death in cortical culture.
    Kim YH; Koh JY
    Exp Neurol; 2002 Oct; 177(2):407-18. PubMed ID: 12429187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.
    Endres M; Wang ZQ; Namura S; Waeber C; Moskowitz MA
    J Cereb Blood Flow Metab; 1997 Nov; 17(11):1143-51. PubMed ID: 9390645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
    Virág L; Szabó C
    Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion.
    Szabó C; Dawson VL
    Trends Pharmacol Sci; 1998 Jul; 19(7):287-98. PubMed ID: 9703762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
    Virág L
    Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress.
    Decker P; Muller S
    Curr Pharm Biotechnol; 2002 Sep; 3(3):275-83. PubMed ID: 12164482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAD+ as a metabolic link between DNA damage and cell death.
    Ying W; Alano CC; Garnier P; Swanson RA
    J Neurosci Res; 2005 Jan 1-15; 79(1-2):216-23. PubMed ID: 15562437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.
    Komjáti K; Besson VC; Szabó C
    Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):179-94. PubMed ID: 15857303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection.
    McCullough LD; Zeng Z; Blizzard KK; Debchoudhury I; Hurn PD
    J Cereb Blood Flow Metab; 2005 Apr; 25(4):502-12. PubMed ID: 15689952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
    Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
    J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural inhibitors of poly(ADP-ribose) polymerase-1.
    Banasik M; Stedeford T; Strosznajder RP
    Mol Neurobiol; 2012 Aug; 46(1):55-63. PubMed ID: 22476980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of poly(ADP-ribose) polymerase-1 in CNS disease.
    Kauppinen TM; Swanson RA
    Neuroscience; 2007 Apr; 145(4):1267-72. PubMed ID: 17084037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-ribosyl)ation basally activated by DNA strand breaks reflects glutamate-nitric oxide neurotransmission.
    Pieper AA; Blackshaw S; Clements EE; Brat DJ; Krug DK; White AJ; Pinto-Garcia P; Favit A; Conover JR; Snyder SH; Verma A
    Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1845-50. PubMed ID: 10677544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ADP-ribose) polymerase-1: a novel therapeutic target in necrotizing enterocolitis.
    Giannone PJ; Alcamo AA; Schanbacher BL; Nankervis CA; Besner GE; Bauer JA
    Pediatr Res; 2011 Jul; 70(1):67-71. PubMed ID: 21399558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-ribose) polymerase-1 in the nervous system.
    Ha HC; Snyder SH
    Neurobiol Dis; 2000 Aug; 7(4):225-39. PubMed ID: 10964595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
    de la Lastra CA; Villegas I; Sánchez-Fidalgo S
    Curr Pharm Des; 2007; 13(9):933-62. PubMed ID: 17430191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.
    Tentori L; Portarena I; Graziani G
    Pharmacol Res; 2002 Feb; 45(2):73-85. PubMed ID: 11846617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.